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Summary 
Background Comparison of patients with coronary heart disease and controls in genome-wide association studies has 
revealed several single nucleotide polymorphisms (SNPs) associated with coronary heart disease. We aimed to establish 
the external validity of these ﬁ ndings and to obtain more precise risk estimates using a prospective cohort design.
Methods We tested 13 recently discovered SNPs for association with coronary heart disease in a case-control design 
including participants diﬀ ering from those in the discovery samples (3829 participants with prevalent coronary heart 
disease and 48 897 controls free of the disease) and a prospective cohort design including 30 725 participants free of 
cardiovascular disease from Finland and Sweden. We modelled the 13 SNPs as a multilocus genetic risk score and 
used Cox proportional hazards models to estimate the association of genetic risk score with incident coronary heart 
disease. For case-control analyses we analysed associations between individual SNPs and quintiles of genetic risk 
score using logistic regression.
Findings In prospective cohort analyses, 1264 participants had a ﬁ rst coronary heart disease event during a median 
10·7 years’ follow-up (IQR 6·7–13·6). Genetic risk score was associated with a ﬁ rst coronary heart disease event. When 
compared with the bottom quintile of genetic risk score, participants in the top quintile were at 1·66-times increased 
risk of coronary heart disease in a model adjusting for traditional risk factors (95% CI 1·35–2·04, p value for linear 
trend=7·3×10–¹⁰). Adjustment for family history did not change these estimates. Genetic risk score did not improve 
C index over traditional risk factors and family history (p=0·19), nor did it have a signiﬁ cant eﬀ ect on net reclassiﬁ cation 
improvement (2·2%, p=0·18); however, it did have a small eﬀ ect on integrated discrimination index (0·004, p=0·0006). 
Results of the case-control analyses were similar to those of the prospective cohort analyses.
Interpretation Using a genetic risk score based on 13 SNPs associated with coronary heart disease, we can identify the 
20% of individuals of European ancestry who are at roughly 70% increased risk of a ﬁ rst coronary heart disease event. 
The potential clinical use of this panel of SNPs remains to be deﬁ ned.
Funding The Wellcome Trust; Academy of Finland Center of Excellence for Complex Disease Genetics; US National 
Institutes of Health; the Donovan Family Foundation.
Introduction 
Coronary heart disease is complex in origin, with 
contributions from lifestyle and genetic factors.1 Family 
history of premature coronary heart disease is an 
independent risk factor, suggesting that inherited DNA 
sequence variants contribute to risk of the disease. Using 
a case-control design, genome-wide association studies 
have identiﬁ ed single nucleotide polymorphisms (SNPs) 
at 13 genomic regions associated (p<5×10–⁸) with 
coronary heart disease, myocardial infarction, or both.2 
In discovery studies, each copy of the risk allele at these 
loci was estimated to increase risk of myocardial 
infarction by 12–92%.
Discovery genome-wide association studies for 
myocardial infarction or coronary heart disease have 
ascertained cases on the basis of early age of disease onset 
or aﬀ ected family members, and as such the reported 
eﬀ ect estimates might not be representative of the general 
population. Although eﬃ  cient for discovery, cross-
sectional and case-control designs have the potential for 
several types of bias, whereas the prospective cohort study 
is regarded as the gold standard in epidemiological 
investigations.3 Therefore, we set out to answer two 
questions: ﬁ rst, are the reported genetic association 
ﬁ ndings externally generalisable in studies diﬀ ering from 
the discovery studies; and second, can more precise risk 
estimates be obtained with a prospective cohort design?
Methods
Study populations 
We tested the 13 recently discovered SNPs for association 
with coronary heart disease in two designs: a case-control 
design including participants diﬀ ering from those in the 
discovery samples (3829 participants with prevalent 
coronary heart disease and 48 897 controls free of the 
disease); and a prospective cohort design including 
30 725 participants free of cardiovascular disease from 
Finland and Sweden. Coronary heart disease was deﬁ ned 
as myocardial infarction, unstable angina pectoris, 
coronary revascularisation (coronary artery bypass graft 
or percutaneous transluminal coronary angioplasty), or 
death due to coronary heart disease. Cardiovascular 
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disease included coronary heart disease and ischaemic 
stroke events. Detailed case deﬁ nitions are described in 
the webappendix.
Participants from seven cohorts were included in our 
analyses (table 1). The FINRISK 1992, 1997, and 2002 
cohorts consist of a representative random sample 
selected from inhabitants of diﬀ erent regions in Finland 
aged 25–74 years. The survey included a mailed 
questionnaire and a clinical examination at which a 
blood sample was drawn. The study protocol has been 
described previously.4 23 036 individuals participated in 
these cohorts and genotype data was available from 
20 927 participants.
The Health 2000 study was based on a stratiﬁ ed 
two-stage cluster sampling from the National Population 
Register to represent the total Finnish population aged 
30 years and older.5 The survey included an interview 
about medical history, health-related lifestyle habits, and 
a clinical examination at which a blood sample was 
drawn. 6200 people participated in the study. After 
exclusion of individuals older than 80 years and without 
suﬃ  cient genotype data, the ﬁ nal dataset consisted of 
5796 participants. A detailed methodology report is 
available online.6
The Malmö Diet and Cancer (MDC) study was a 
community-based prospective epidemiological cohort of 
28 449 people recruited for a baseline examination 
between 1991 and 1996.7 From this cohort, 6103 people 
were randomly selected to participate in the Cardiovascular 
Cohort (MDC-CC), which sought to investigate risk 
factors for cardiovascular disease. All participants 
underwent a medical history, physical examination, and 
laboratory assessment for cardiovascular risk factors, as 
described previously.8 Final data with genotypes were 
available for 5104 participants.
During follow-up of the FINRISK and HEALTH 2000 
cohorts, data for admission to hospital and mortality 
were obtained from the Finnish National Hospital 
Discharge Register and the Finnish National Causes-of-
Death Register. These registers have excellent validity 
and coverage.9,10 Follow-up ended on Dec 31, 2007. 
Follow-up of the MDC-CC is as previously described.11
The Malmö Preventive Project (MPP) is a cohort from 
southern Sweden that was set up in 1974. 33 346 individuals 
were screened during 1974–92. Information concerning 
lifestyle factors and medical history was obtained from a 
questionnaire. All participants underwent physical 
examination and biochemical analyses. Of individuals 
FR 1992 
(n=5353)
FR 1997 
(n=7939)
FR 2002 
(n=7635)
Health 2000 
(n=5796)
MDC-CC
 (n=5104)
COROGENE 
(n=6015)
MPP 
(n=14 884)
Sex
Male 2449 (46%) 4006 (50%) 3526 (46%) 2697 (47%) 2141 (42%) 4192 (70%) 9773 (66%)
Female 2904 (54%) 3933 (50%) 4109 (54%) 3099 (53%) 2963 (58%) 1823 (30%) 5111 (34%)
Age (years) 44·5 (11·3) 49 (13·4) 48·4 (13·1) 50·8 (13·0) 57·4 (5·9) 66·5 (10·9) 45·3 (7·0)
Cholesterol
Total (mmol/L) 5·6 (1·1) 5·5 (1·1) 5·6 (1·1) 5·9 (1·1) 6·2 (1·1) NA 5·6 (1·0)
LDL (mmol/L) 3·5 (1·0) 3·5 (0·9) 3·4 (0·9) 3·8 (1·2) 4·2 (1·0) NA NA
HDL (mmol/L) 1·4 (0·3) 1·4 (0·4) 1·5 (0·4) 1·3 (0·4) 1·4 (0·4) NA NA
Blood pressure
Systolic (mm Hg) 135·3 (19·4) 136·2 (20·1) 135·0 (20·0) 133·7 (20·6) 141·1 (18·9) NA 127·7 (14·4)
Diastolic (mm Hg) 81·2 (11·9) 82·4 (11·3) 79·1 (11·4) 82·1 (11·2) 86·9 (9·5) NA 84·2 (8·8)
Body-mass index (kg/m²) 26·1 (4·4) 26·7 (4·5) 26·9 (4·7) 26·9 (4·7) 25·9 (4·9) NA 24·4 (3·4)
Current smoker 1498 (28%) 1846 (23%) 1993 (26%) 1728 (30%) 1307 (26%) NA 5639 (38%)
Current drug therapy
Lipid-lowering 82 (2%) 280 (4%) 563 (7%) 1396 (24%) 109 (2%) NA NA
Antihypertensive 496 (9%) 1056 (13%) 1095 (14%) 1306 (23%) 641 (13%) NA 645 (4%)
Diabetes mellitus 198 (4%) 481  (6%) 433 (6%) 460 (8%) 399 (8%) NA 617 (4%)
Prevalent cases
CHD 64 (1%) 222 (3%) 198 (3%) 59 (1%) NA NA NA
CVD 77 (1%) 276 (3%) 264 (3%) 378 (7%) 107 (2%) NA 1749 (12%)
MI 50 (1%) 161 (2%) 119 (2%) 28 (<1%) 63 (1%) 2101 (35%) 1122 (8%)
Incident cases
CHD 296 (6%) 419 (5%) 132 (2%) 151 (3%) NA NA NA
CVD 416 (8%) 599 (8%) 186 (2%) 201 (3%) 468 (9%) NA NA
MI 157 (3%) 230 (3%) 65 (1%) 112 (2%) 266 (5%) NA NA
Data are mean (SD) or number (%). FR=FINRISK. MDC-CC=Malmö Diet and Cancer Cardiovascular cohort. MPP=Malmö Preventive Project. NA=not available. CHD=coronary 
heart disease. CVD=cardiovascular disease. MI=myocardial infarction.
Table 1: Background characteristics of  the seven study populations
See Online for webappendix
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who participated in the baseline examinations, 17 284 were 
rescreened during 2002–06. The ﬁ nal data with genotypes 
included 14 884 individuals.
For the COROGENE cohort, initially, all consecutive 
Finnish patients undergoing coronary angiogram 
between June, 2006, and March, 2008 (n=5330), in the 
Helsinki University Central Hospital were included and 
a questionnaire, information about previous medical 
conditions and cardiovascular risk factors, hospital 
records for patients’ history, laboratory measurements, 
electrocardiogram, echocardiogram, and medication 
were obtained. Of these patients, 2118 (53%) had acute 
coronary syndrome and were selected as COROGENE 
cases. The controls for COROGENE cases were selected 
from the Helsinki-Vantaa region participants of 
FINRISK 1997, 2002, and 2007 by risk set sampling.12 
For each case, two controls matched by sex and birth 
year and free of acute coronary syndrome were sampled. 
In total, 2101 cases and 3914 controls (of which 1453 were 
unique) formed the ﬁ nal genotyped COROGENE case-
control sample. 
The FINRISK 1992, 1997, 2002 and Health 2000 study 
protocols were approved by the ethics committee of the 
National Institute for Health and Welfare, the MDC-CC 
and MPP study protocols by the ethics committee of 
Lund University, and the COROGENE study protocol 
by the ethics committee of Helsinki University Hospital, 
Internal Medicine. All participants provided written 
informed consent.
SNP selection and genotyping
We selected SNPs from genome-wide association studies 
published before June, 2009 in which phenotypes studied 
were myocardial infarction or coronary heart disease, and 
association between a SNP and myocardial infarction or 
coronary heart disease exceeded a genome-wide associ-
ation threshold (p<5×10–⁸). 13 SNPs from seven reports13–19 
met these criteria, including 1q41 in MIA3, 1p32 near 
PCSK9, 1p13 near CELSR2–PSRC1–SORT1, 2q33 in 
WDR12, 6p24 in PHACTR1, 9p21 near CDKN2A–CDKN2B, 
10q11 near CXCL12, 19p13 near LDLR, 21q22 near SLC5A3–
MRPS6–KCNE2, 3q22 in MRAS, 6q26 in LPA, 12q24 near 
HNF1A, and 12q24 in SH2B3.
Samples were genotyped with the Sequenom platform 
(iPlex MassARRAY, San Diego, CA, USA) at the Institute 
for Molecular Medicine Finland FIMM (FINRISK 1992 
and 2002), the Wellcome Trust Sanger Institute, 
UK (Health 2000), or the Broad Institute, USA 
(FINRISK 1997 and MDC-CC), and with Sequenom or 
Taqman (Applied Biosystems, Foster City, CA, USA) 
platforms at Lund University, Sweden (MDC-CC and MPP). 
COROGENE was genotyped with Illumina 610K chip 
(Illumina HumanHap 610-Quad SNP array, San Diego, 
CA, USA) at the Sanger Institute. Genotypes were manually 
curated with call rates above 97%.
Statistical analysis
We tested associations between SNPs and incident 
cardiovascular events using Cox proportional hazards 
Region Candidate
gene(s)
Weight† Reference† Risk 
allele
Risk allele 
frequency
Other 
allele
Coronary heart disease 
(total n=19 790)
Cardiovascular disease 
(total n=24 894)
Myocardial infarction 
(total n=24 894)
Pooled HR 
(95% CI)‡
p value Pooled HR 
(95% CI)‡
p value Pooled HR 
(95% CI)‡
p value
rs17465637 1q41 MIA3 1·14 15 C 0·75 A 0·99 (0·87–1·12) 0·854 1·03 (0·94–1·12) 0·546 1·03 (0·91–1·18) 0·624
rs11206510 1p32 PCSK9 1·15 15 T 0·84 C 0·94 (0·81–1·09) 0·431 0·97 (0·87–1·07) 0·515 1·04 (0·89–1·22) 0·636
rs646776 1p13 CELSR2– 
PSRC1– 
SORT1
1·19 15 T 0·79 C 0·96 (0·84–1·09) 0·512 0·98 (0·89–1·07) 0·587 0·94 (0·82–1·08) 0·378
rs6725887 2q33 WDR12 1·17 15 C 0·11 T 1·14 (0·96–1·35) 0·126 1·00 (0·89–1·12) 0·960 0·96 (0·80–1·14) 0·629
rs9818870 3q22 MRAS 1·15 16 T 0·10 C 0·88 (0·73–1·06) 0·174 0·92 (0·81–1·03) 0·150 0·86 (0·71–1·03) 0·097
rs3798220 6q26 LPA 1·68 18 C 0·01 T 2·07 (1·39–3·09) 3·8×10–5 1·63 (1·22–2·17) 0·001 1·80 (1·19–2·72) 0·005
rs9349379 6p24 PHACTR1 1·12 15 C 0·44 T 1·16 (1·04–1·29) 0·008 1·10 (1·02–1·19) 0·014 1·11 (0·99–1·24) 0·075
rs4977574 9p21 CDKN2A –
CDKN2B
1·29 15 G 0·43 A 1·21 (1·08–1·34) 0·001 1·16 (1·08–1·25) 9·3×10–6 1·19 (1·06–1·33) 0·002
rs1746048 10q11 CXCL12 1·17 15 C 0·84 T 1·13 (0·97–1·33) 0·113 1·01 (0·91–1·12) 0·846 1·11 (0·95–1·31) 0·198
rs2259816 12q24 HNF1A 1·08 16 T 0·36 G 1·02 (0·91–1·14) 0·774 1·00 (0·92–1·08) 0·932 1·01 (0·90–1·14) 0·836
rs3184504 12q24 SH2B3 1·13 17 T 0·40 C 1·03 (0·92–1·15) 0·568 1·10 (1·02–1·19) 0·011 1·15 (1·03–1·29) 0·012
rs1122608 19p13 LDLR 1·15 15 G 0·79 T 1·00 (0·87–1·14) 0·988 1·02 (0·93–1·12) 0·693 0·98 (0·86–1·12) 0·774
rs9982601 21q22 SLC5A3– 
MRPS6–
KCNE2
1·20 15 T 0·14 C 1·29 (1·07–1·57) 0·009 1·11 (0·98–1·26) 0·092 1·24 (1·04–1·48) 0·016
SNP=single nucleotide polymorphism. HR=hazard ratio. *Association tested with Cox proportional hazards model adjusted for sex, LDL and HDL cholesterol, smoking, body-mass index, systolic and diastolic 
blood pressure, blood pressure treatment, and diabetes; age was used as the timescale. †SNP speciﬁ c weights for genetic risk score calculation; weights are eﬀ ect sizes for the SNPs from the studies referenced. 
‡Results from FINRISK 1992, 1997, and 2002, Health 2000, and Malmö Diet and Cancer Cardiovascular Cohort were combined with ﬁ xed eﬀ ects meta-analysis.21
Table 2: Association between SNPs and incident coronary heart disease, cardiovascular disease, and myocardial infarction*
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models adjusted for traditional risk factors: sex, 
LDL and HDL cholesterol, current cigarette smoking, 
body-mass index, systolic and diastolic blood pressure, 
blood pressure treatment, and prevalent type 2 diabetes. 
Age was used as the baseline timescale in the Cox models. 
The proportional hazards assumption was met when 
tested with scaled Schoenfeld residuals.20
We constructed a multilocus genetic risk score for each 
individual by summing the number of risk alleles (0/1/2) 
for each of the 13 SNPs weighted by their estimated 
eﬀ ect sizes in the discovery sample (table 2 shows SNP 
speciﬁ c weights). Missing genotype values were imputed 
with the cohort-speciﬁ c averages of risk allele frequencies. 
Estimates of association between the genetic risk score 
divided into quintiles and time to coronary heart disease, 
cardiovascular disease, and myocardial infarction were 
calculated with Cox proportional hazards models. For 
each cohort we calculated 95% CIs for hazard ratios 
(HRs) and tested the null hypothesis of no linear eﬀ ect 
over the quintiles using 1 df Wald test. 
For prevalent case-control analyses, we analysed 
individual SNP and quintiles of genetic risk score 
associations using a logistic regression model adjusted 
for age and sex. COROGENE data were analysed with 
conditional logistic regression. Each cohort was analysed 
separately, and the estimates weighted on the inverse of 
their standard errors were combined across cohorts with 
ﬁ xed eﬀ ects meta-analysis.21
To evaluate the potential value of genetic risk score in 
risk prediction, we used two cohorts (FINRISK 1992 
and 1997) and up to 10-year follow-up. First, we compared 
the receiver operating characteristic (ROC) curves22 of 
models with and without genetic risk score. The 
statistical signiﬁ cance of change in the area under the 
ROC curve (AUC) between models was tested with the 
correlated C-index approach.23 Second, we calculated net 
reclass iﬁ cation improvement (NRI) and clinical NRI24 
using the Kaplan-Meier approach with bootstrap-based 
p values,25 and integrated discrimination improve ment 
(IDI).26 The model calibration was tested with Hosmer-
Lemeshow goodness-of-ﬁ t test. 
Since each of the 13 reported SNPs has previously 
been associated with coronary heart disease or 
myocardial infarction at signiﬁ cance levels exceeding a 
stringent genome-wide threshold, in this report we 
regarded an association to be signiﬁ cant if a two-
sided p value was less than 0·05 (for the same risk 
allele in the same direction as in the original report). 
The R statistical package (version 2.11.1) was used for 
all analyses.
Role of the funding source
The sponsors had no role in the conduct or interpretation 
of the study. The corresponding author had full access to 
all data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
Genetic risk score quintile p value for trend
1 (reference) 2 3 4 5
HR (95% CI) for CHD (total  n=25 243)
FR 1992 1·00 0·97 (0·65–1·45) 1·07 (0·71–1·60) 1·60 (1·10–2·34) 1·54 (1·06–2·25) 0·001
FR 1997 1·00 1·02 (0·72–1·44) 1·17 (0·84–1·62) 1·32 (0·95–1·83) 1·76 (1·28–2·41) 1·1×10–5
FR 2002 1·00 1·06 (0·56–1·99) 1·18 (0·65–2·15) 1·43 (0·79–2·58) 1·82 (1·03–3·22) 0·019
Health 2000 1·00 0·93 (0·51–1·68) 1·41 (0·81–2·45) 1·13 (0·62–2·06) 1·51 (0·87–2·62) 0·087
Pooled† 1·00 1·00 (0·80–1·25) 1·17 (0·94–1·46) 1·39 (1·12–1·72) 1·66 (1·35–2·04) 7·3×10–10
HR (95% CI) for CVD (total n=29 318)
FR 1992 1·00 1·03 (0·74–1·43) 1·10 (0·79–1·54) 1·35 (0·98–1·87) 1·55 (1·14–2·12) 0·001
FR 1997 1·00 0·88 (0·66–1·18) 1·12 (0·86–1·46) 1·20 (0·92–1·58) 1·54 (1·18–1·99) 1·1×10–5
FR 2002 1·00 1·18 (0·70–2·00) 1·43 (0·87–2·36) 1·33 (0·79–2·23) 2·01 (1·24–3·25) 0·004
Health 2000 1·00 1·03 (0·63–1·69) 1·31 (0·81–2·12) 1·30 (0·80–2·12) 1·70 (1·08–2·68) 0·009
MDC-CC 1·00 0·83 (0·57–1·19) 0·82 (0·57–1·18) 0·75 (0·51–1·10) 1·13 (0·80–1·58) 0·511
Pooled† 1·00 0·95 (0·80–1·12) 1·10 (0·93–1·29) 1·16 (0·99–1·36) 1·50 (1·29–1·75) 1·9×10–10
HR (95% CI) for MI (total n=29 318)
FR 1992 1·00 1·00 (0·57–1·73) 1·00 (0·57–1·77) 1·60 (0·95–2·69) 1·45 (0·86–2·44) 0·039
FR 1997 1·00 1·02 (0·63–1·65) 1·36 (0·87–2·11) 1·32 (0·84–2·08) 1·87 (1·21–2·87) 0·002
FR 2002 1·00 1·22 (0·50–2·95) 0·89 (0·35–2·26) 1·16 (0·48–2·81) 2·05 (0·92–4·60) 0·095
Health 2000 1·00 0·89 (0·44–1·81) 1·68 (0·89–3·17) 1·00 (0·48–2·05) 1·35 (0·70–2·62) 0·320
MDC-CC 1·00 0·93 (0·58–1·51) 0·78 (0·47–1·28) 0·89 (0·55–1·46) 1·03 (0·65–1·64) 0·891
Pooled† 1·00 0·99 (0·76–1·27) 1·11 (0·87–1·43) 1·19 (0·93–1·53) 1·46 (1·15–1·86) 2·8×10–5
HR=hazard ratio. CHD=coronary heart disease. FR=FINRISK. CVD=cardiovascular disease. MDC-CC=Malmö Diet and Cancer Cardiovascular cohort. MI=myocardial infarction. 
*Association tested with Wald test with a Cox proportional hazards model adjusted for sex, LDL and HDL cholesterol, smoking, body-mass index, systolic and diastolic blood 
pressure, blood pressure treatment and diabetes; age was used as the timescale. †Results were combined with ﬁ xed eﬀ ects meta-analysis.21 
Table 3: Association between genetic risk score and incident coronary heart disease, cardiovascular disease, and myocardial infarction*
Articles
www.thelancet.com   Vol 376   October 23, 2010 1397
Results
52 726 participants in FINRISK 1992, 1997, and 2002, 
Health 2000, MDC-CC, MPP, and COROGENE were 
included in our analysis of prevalent cases versus controls. 
The total number of prevalent cases of coronary heart 
disease was 3829 (7%). 30 725 participants from ﬁ ve cohorts 
(FINRISK 1992, 1997, and 2002, Health 2000, and MDC-
CC) were included in the prospective cohort analyses. 
Median follow-up was 10·7 years (IQR 6·7–13·6). 
1264 (4%) incident cases of coronary heart disease occurred 
during follow-up. Table 1 shows background characteristics 
along with risk factor distributions for the cohorts. 
In single SNP analyses for prevalent cases, 9p21 near 
CDKN2A–CDKN2B, 21q22 near SLC5A3–MRPS6–
KCNE2, and 1q41 in MIA3 were associated with coronary 
heart disease, cardiovascular disease, and myocardial 
infarction, and 19p13 near LDLR was associated with 
prevalent coronary heart disease (webappendix p 2). In 
analysis of incident cases, 6q26 in LPA and 9p21 near 
CDKN2A–CDKN2B were associated with all three 
endpoints. Additionally, 6p24 in PHACTR1 was associated 
with incident coronary heart disease and cardiovascular 
disease, 12q24 in SH2B3 with cardiovascular disease and 
myocardial infarction, and 21q22 near SLC5A3–MRPS6–
KCNE2 with coronary heart disease and myocardial 
infarction (table 2). Overall, seven of the 13 variants were 
associated in at least one analysis.
Genetic risk score was strongly associated with incident 
coronary heart disease, cardiovascular disease, and 
myocardial infarction when adjusted for age and sex 
(webappendix p 3) and traditional risk factors (table 3). 
Adjustment for traditional risk factors did not substantially 
change the estimates from the model adjusted for age 
and sex only. Participants in the top quintile of genetic 
risk score were estimated to have 1·66-times increased 
risk of coronary heart disease compared with those in the 
bottom quintile (95% CI 1·35–2·04, p value for linear 
trend across the quintiles=7·3×10–¹⁰), 1·50-times increased 
risk of cardiovascular disease (95% CI 1·29–1·75, 
p=1·9×10–¹⁰), and 1·46-times increased risk of myocardial 
infarction (95% CI 1·15–1·86, p=2·8×10–⁵). 
Results were broadly similar when the genetic risk score 
was divided into tertiles. In models adjusted for trad-
itional risk factors, participants in the top tertile of the 
genetic risk score were estimated to have a 1·56-times 
increased risk of coronary heart disease compared with 
those in the bottom tertile (95% CI 1·33–1·83, p value for 
linear trend across tertiles=2·8×10–⁸), 1·40-times increased 
risk of cardiovascular disease (95% CI 1·24–1·58, 
p=1·4×10–⁸), and 1·34-times increased risk of myocardial 
infarction (95% CI 1·12 –1·62, p=0·0015).
The genetic risk score conferred risk comparable to other 
established risk factors such as plasma LDL cholesterol 
(HR 2·08, 95% CI 1·57–2·76, for top vs bottom quintile of 
LDL cholesterol in FINRISK studies), systolic blood 
pressure (HR 1·66, 95% CI 1·19–2·30, for top vs bottom 
quintile of systolic blood pressure in FINRISK studies), or 
plasma C-reactive protein (HR 1·79, 95% CI 1·15–2·80, for 
top vs bottom quintile in FINRISK studies). Although the 
group means were statistically diﬀ erent, the distribution of 
each quantitative risk factor between those who went on to 
develop coronary heart disease and those who did not was 
broadly overlapping (ﬁ gure).
Table 4 shows results for prevalent events. The odds ratio 
for coronary heart disease between the highest and lowest 
quintile group was 1·63 (95% CI 1·24–2·15, p=4·8×10–⁵), 
for cardiovascular disease was 1·30 (95% CI 1·15–1·47, 
p=2·6×10–⁸), and for myocardial infarction was 1·56 
(95% CI 1·38–1·76, p=1·2×10–¹⁵).
Additionally, we investigated whether adjustment for a 
history of early-onset myocardial infarction among 
ﬁ rst-degree relatives changed genetic risk score estimates 
in the FINRISK studies. Family history was signiﬁ cantly 
associated with incident events (HR for coronary heart 
disease 1·40, 95% CI 1·20–1·64; webappendix p 4), but 
the eﬀ ect of the genetic risk score did not change after 
adjustment for family history (webappendix p 5). 
We then investigated whether the genetic risk score 
association was dominated by rs4977574 at 9p21 near 
CDKN2B–CDKN2A, which is the strongest myocardial 
infarction locus reported to date. After adjustment 
for rs4977574, the HR between the highest and lowest 
genetic risk score quintile was 1·51 (95% CI 1·19–1·91) 
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Figure: Distributions at baseline of genetic risk score, LDL cholesterol, systolic blood pressure, and 
log-transformed C-reactive protein by 10-year incident coronary heart disease event status in 
FINRISK 1992 and 1997 cohorts
Data for C-reactive protein only available in FINRISK 1997. CHD=coronary heart disease.
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for coronary heart disease. Thus, other variants in the 
genetic risk score seem to have predictive power beyond 
the 9p21 locus (webappendix p 5). 
The AUC estimates for coronary heart disease, 
cardiovascular disease, and myocardial infarction 
models with traditional risk factors and genetic risk 
score were 0·872, 0·853, and 0·881, respectively, and 
they were not signiﬁ cantly higher than the estimates 
from the models with only traditional risk factors 
(0·871, p=0·19; 0·853, p=0·48; and 0·880, p=0·35, for 
coronary heart disease, cardiovascular disease, and 
myocardial infarction, respectively). 
Table 5 and table 6 show risk reclassiﬁ cation results for 
coronary heart disease. When participants were classiﬁ ed 
into four risk categories (0–5%, 5–10%, 10–20%, 
and >20%) on the basis of their 10-year predicted risk, 
22 (13%) participants with coronary heart disease 
classiﬁ ed at 10–20% risk category in the model with 
traditional risk factors changed their risk category into 
the greater than 20% category when genetic risk score 
was included in the model. Similarly, 54 (13%) of the 
participants without incident coronary heart disease were 
reclassiﬁ ed from the greater than 20% to the 
10–20% category. IDI was signiﬁ cant for coronary heart 
disease (IDI 0·004, p=0·0006), cardiovascular disease 
(IDI 0·004, p=0·0004), and for myocardial infarction 
(IDI 0·003, p=0·03). For coronary heart disease, overall 
NRI was not signiﬁ cant (NRI 2·2%, p=0·182), but there 
was a signiﬁ cant improvement in reclassiﬁ cation of 
participants at intermediate risk (clinical NRI 9·7%, 
p=3×10–⁶). The calibration of the models with (p=0·52) 
and without (p=0·47) genetic risk score was good.
Genetic risk score quintile p value for trend
1 (reference) 2 3 4 5
OR (95% CI) for CHD (total n=29 318)
FR 1992 1·00 2·30 (0·93–5·69) 1·22 (0·43–3·40) 2·67 (1·10–6·46) 2·13 (0·84–5·36) 0·117
FR 1997 1·00 0·95 (0·62–1·47) 0·86 (0·56–1·33) 0·86 (0·55–1·35) 1·32 (0·87–2·01) 0·341
FR 2002 1·00 1·01 (0·60–1·71) 1·55 (0·96–2·51) 1·32 (0·79–2·19) 2·03 (1·26–3·25) 0·002
Health 2000 1·00 1·56 (0·76–3·22) 1·67 (0·80–3·47) 1·96 (0·97–3·99) 1·58 (0·78–3·23) 0·184
Pooled† 1·00 1·15 (0·86–1·53) 1·20 (0·90–1·59) 1·27 (0·95–1·70) 1·63 (1·24–2·15) 4·8×10–5
OR (95% CI) for CVD (total n=47 179)
FR 1992 1·00 1·7 (0·76–3·78) 0·95 (0·38–2·38) 2·49 (1·17–5·29) 1·69 (0·76–3·80) 0·090
FR 1997 1·00 0·89 (0·6–1·32) 0·87 (0·59–1·28) 0·81 (0·54–1·21) 1·26 (0·87–1·84) 0·396
FR 2002 1·00 1·10 (0·71–1·69) 1·36 (0·90–2·05) 1·17 (0·76–1·81) 1·63 (1·09–2·46) 0·022
Health 2000 1·00 0·97 (0·71–1·33) 1·12 (0·82–1·53) 1·04 (0·76–1·42) 1·16 (0·86–1·57) 0·275
MDC-CC 1·00 1·78 (0·89–3·54) 2·32 (1·20–4·48) 1·39 (0·68–2·87) 1·58 (0·79–3·17) 0·502
MPP 1·00 0·97 (0·82–1·15) 1·11 (0·94–1·30) 1·34 (1·14–1·57) 1·27 (1·08–1·49) 1·0×10–5
Pooled† 1·00 1·01 (0·89–1·15) 1·13 (1·00–1·28) 1·24 (1·09–1·40) 1·30 (1·15–1·47) 2·6×10–8
OR (95% CI) for MI (total n=53 741)
FR 1992 1·00 2·83 (1·00–7·97) 1·07 (0·30–3·73) 2·51 (0·88–7·16) 2·79 (0·98–7·94) 0·120
FR 1997 1·00 0·95 (0·58–1·56) 0·76 (0·46–1·27) 1·08 (0·67–1·76) 1·01 (0·61–1·68) 0·807
FR 2002 1·00 0·97 (0·49–1·93) 1·88 (1·03–3·43) 1·52 (0·80–2·90) 1·82 (0·98–3·38) 0·023
Health 2000 1·00 1·44 (0·54–3·85) 1·28 (0·45–3·61) 2·70 (1·09–6·66) 1·58 (0·61–4·09) 0·142
MDC-CC 1·00 2·35 (0·90–6·18) 2·39 (0·92–6·22) 1·51 (0·53–4·27) 2·97 (1·18–7·50) 0·092
MPP 1·00 1·04 (0·85–1·28) 1·05 (0·86–1·29) 1·38 (1·13–1·67) 1·33 (1·10–1·62) 1·1×10–5
COROGENE 1·00 1·23 (1·03–1·46) 1·36 (1·14–1·62) 1·40 (1·18–1·67) 1·75 (1·48–2·08) 8·8×10–12
Pooled† 1·00 1·16 (1·03–1·31) 1·22 (1·08–1·38) 1·40 (1·24–1·58) 1·56 (1·38–1·76) 1·2×10–15
OR=odds ratio. CHD=coronary heart disease. FR=FINRISK. CVD=cardiovascular disease. MDC-CC=Malmö Diet and Cancer Cardiovascular Cohort. MPP=Malmö Preventive 
Project. MI=myocardial infarction. *Association tested with Wald test with a logistic regression adjusted for age and sex; COROGENE data with matched case-control design 
was analysed with conditional logistic regression. †Results were combined with ﬁ xed eﬀ ects meta-analysis.21
Table 4: Association between genetic risk score and prevalent coronary heart disease, cardiovascular disease, and myocardial infarction*
Genetic risk 
score 0–5%
Genetic risk 
score 5–10%
Genetic risk 
score 10–20%
Genetic risk 
score >20% 
Cases, by predicted risk*
0–5% 82 (93%) 6 (7%) 0 0
5–10% 10 (8%) 100 (84%) 9 (8%) 0
10–20% 0 9 (5%) 136 (81%) 22 (13%)
>20% 0 0 9 (7%) 129 (93%)
Non-cases, by predicted risk*
0–5% 9224 (99%) 121 (1%) 0 0
5–10% 179 (12%) 1149 (79%) 131 (9%) 0
10–20% 0 120 (14%) 687 (80%) 49 (6%)
>20% 0 0 54 (13%) 351 (87%)
*10-year predicted risk on the basis of traditional risk factors only.
Table 5: Reclassiﬁ cation of individuals in the FINRISK 1992 and 1997 
cohorts on the basis of 10-year predicted risk of coronary heart disease 
with and without genetic risk score
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Discussion
Using case-control and prospective cohort samples 
independent from the discovery samples, we sought to 
validate recently discovered genetic risk factors for 
coronary heart disease and to estimate the magnitude of 
risk conferred by these genetic risk factors in the 
population setting. We found that a genetic risk score 
including 13 SNPs associated with coronary heart disease 
or myocardial infarction was associated with risk of 
prevalent and incident coronary heart disease (even after 
we accounted for traditional risk factors), and that the 
20% of individuals of European ancestry who carry the 
most risk alleles have a roughly 1·7-times increased risk 
of coronary heart disease when compared with those in 
the lowest quintile. 
These ﬁ ndings allow us to draw several conclusions. 
First, the results from case-control discovery samples do 
seem to generalise to independent samples, including 
those from prospective cohorts. Second, the magnitude 
of eﬀ ect conferred by genetic risk score (roughly 1·7-times 
increased risk in our study) is attenuated when compared 
with the discovery reports (about 2·2-times in one 
report9). Third, even though family history of early-onset 
cardiovascular disease raised the risk of cardiovascular 
events by 25–40%, adjustment for family history had no 
eﬀ ect on the risk estimates because of the genetic risk 
score. In view of measurement error for family history, 
and since genetic variants only account for a small 
proportion of familial risk, this ﬁ nding might not 
be unexpected. 
Finally, although strongly associated with risk of incident 
coronary heart disease, genetic risk score did not improve 
risk discrimination when assessed by the C index. This 
ﬁ nding of a biomarker being associated with incident 
disease but yet not improving risk discrimination has been 
seen with several other biomarkers, including 
C-reactive protein and B-type natriuretic peptide, among 
others.27 Since some have argued that the C index might be 
an insensitive measure of risk discrimination, newer 
approaches have been developed, including IDI, NRI, and 
clinical NRI. The tested genetic risk score slightly improved 
risk prediction for coronary heart disease and myocardial 
infarction when assessed by IDI and clinical NRI. Overall, 
these results emphasise the challenge of risk prediction for 
complex traits on the basis of any single factor.28
Our combined results show much larger risk diﬀ erences 
between the tails of genetic risk score than in a recently 
reported follow-up study of women enrolled in a clinical 
trial.29 The diﬀ erence cannot be accounted for by the 
inclusion of men in our study, since our estimates and 
predictions are similar for both sexes. Also, nine of the 
genetic loci in our genetic risk score are the same as in 
the cardiovascular disease score reported by Paynter and 
colleagues,29 and the statistical models are comparable. 
We suggest three potential reasons for the diﬀ ering 
results. Paynter and co-workers included a range of 
endpoints such as strokes (203 of the 777 outcomes) that 
have not been associated with the genetic variants studied. 
The inclusion of such outcomes might have diminished 
their eﬀ ect estimates. Second, Paynter and colleagues had 
a small number of myocardial infarction events 
(199 events) and thus lower statistical power might 
account for the absence of association in that study. 
Finally, the women studied were a selected set of health 
professional participants who volunteered for the clinical 
trial and as such might not represent the full range of risk 
seen in the general population.
Although we present the largest eﬀ ort to date to study 
the association between genetic risk score and risk of 
incident cardiovascular disease, our results should be 
interpreted in the context of several potential limitations. 
Our SNP panel could be incomplete. For example, we 
did not systematically evaluate SNPs related to 
cardiovascular risk markers, as Paynter and colleagues 
did.29 Whereas hundreds of blood biomarkers have been 
shown to be associated with cardiovascular disease in 
observational epidemiology research, few have been 
proven to causally relate to the disease; plasma LDL 
cholesterol and lipoprotein(a) are notable exceptions. 
Therefore, we did not consider SNPs that are only 
associated with cardiovascular risk markers. Our study 
was undertaken in individuals of Swedish and Finnish 
descent and hence the results might not be generalisable 
to others in Europe or to other ancestries. We divided 
the continuous genetic risk score into ﬁ ve groups and 
compared risk between the top and bottom quintiles. 
Since alternative categorisations are possible we also 
generated comparisons of the top and bottom third of 
the distribution, and these results were similar to those 
seen with quintiles.
Individuals reclassiﬁ ed in table 5 NRI Clinical NRI†
Up Down Value 95% CI p value Value 95% CI p value
Cases 37 28 0·018 –0·014 to 0·051 0·278 0·041 0·001 to 0·081 0·042
Non-cases 301 353 0·004 0·0001 to 0·008 0·038 0·056 0·044 to 0·069 5×10–18
Total ·· ·· 0·022  –0·010 to 0·055 0·182 0·097 0·056 to 0·140 3×10–6
NRI=net reclassiﬁ cation improvement. *Comparison of models with and without genetic risk score, adjusted for sex, LDL and HDL cholesterol, smoking, body-mass index, 
systolic and diastolic blood pressure, blood pressure treatment, and diabetes; age was used as the timescale. †NRI for the subset of participants in 5–20% risk category in the 
model without genetic risk score, with risk classes 0–5%, 5–20%, and >20%.23
Table 6: Net reclassiﬁ cation improvement of genetic risk score for coronary heart disease in the FINRISK 1992 and 1997 cohorts*
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In conclusion, a genetic risk score based on 13 SNPs 
from genome-wide association studies for myocardial 
infarction and coronary heart disease was associated with 
a ﬁ rst coronary heart disease event, with a relative risk 
estimate of 1·7 between the highest and lowest quintiles 
of genetic risk score. Genetic risk score improved risk 
reclassiﬁ cation in participants who were at intermediate 
risk on the basis of traditional risk factors. Whether this 
genetic risk score will have clinical usefulness remains to 
be deﬁ ned in future studies. 
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